Coriolis contributes to CNAT-M
Coriolis Pharma is part of the Cluster for Nucleic Acid Therapeutics Munich (CNAT-M), an innovation network of science and industry, which aims to develop novel nucleic acid-based therapeutics of the next generation.
Coriolis Pharma will contribute with drug product development expertise and formulation know-how, to enable the transformation from innovative molecules towards drug products suitable for human application. A phase-appropriate support from early developability assessments and pre-formulation work, towards formulation development for lead candidates is planned.
Within the framework of the so-called “Verbundprojekt 1D” for chemically modified nucleosides, nucleotides and oligonucleotides as therapeutics and vaccines Coriolis works closely with the Ludwig-Maximilians-University of Munich, the Helmholtz Center Munich and Dynamic Biosensors, among others.